Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France. Show more

Location: 65, quai Georges Gorse, Boulogne-Billancourt, 92100, France | Website: https://www.ipsen.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

10.77B

52 Wk Range

$25.11 - $32.25

Previous Close

$30.72

Open

$30.72

Volume

60

Day Range

$30.72 - $30.72

Enterprise Value

2.329B

Cash

679.2M

Avg Qtr Burn

N/A

Insider Ownership

0.00%

Institutional Own.

0.01%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Sohonos (Palovarotene) Details
Genetic disorder, Fibrodysplasia ossificans progressiva, Rare genetic disease

Approved

Quarterly sales

Approved

Quarterly sales

Onivyde Details
Cancer, Pancreatic cancer, Carcinoma

Approved

Quarterly sales

Bylvay (Odevixibat) (ileal bile acid transport inhibitor) Details
Progressive familial intrahepatic cholestasis

Approved

Quarterly sales

Elafibranor (dual α,δ PPAR agonist) Details
Cholestatic Liver Disease, Primary biliary cholangitis

Approved

Quarterly sales

Tazverik (Tazemetostat ) Details
NHL (Non-Hodgkins Lymphoma), R/R FL (Relapsed or Refractory Follicular Lymphoma) and ES (Epithelioid Sarcoma)

Approved

Quarterly sales

Phase 3

Data readout

Cabometyx + atezolizumab Details
Cancer, Prostate cancer

Phase 3

Update

Phase 3

Update